Sheena Nunag
Sheena Nunag has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Sherstyuk
Children’s Cancer Institute 1 , Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia
14 shared publications - Andrew S. Moore
Oncology Service, Children’s Health Queensland Hospital and Health Service, Brisbane, Australia
14 shared publications - Ann-Kristin Altekoester
Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre, Sydney, NSW, Australia
14 shared publications - Antoinette Anazodo
Kids Cancer Centre Sydney Children's Hospital Randwick New South Wales Australia
14 shared publications - Ashleigh Sullivan
Oncology Service, Children’s Health Queensland Hospital and Health Service, Brisbane, QLD, Australia
14 shared publications - Bhavna Padhye
Cancer Centre for Children The Children's Hospital at Westmead Westmead New South Wales Australia
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Purpose:The role of germline predisposition in pediatric cancer is increasingly recognized. However, the optimal approach to identifying cancer predisposing germline pathogenic variants (GPV) in children, and even the prevalence of GPVs among children with cancer, remain unclear. We examined GPV prevalence and diagnostic yield of different test approaches within a national pediatric precision oncology program.Experimental Design:We performed prospective rapid-turnaround whole-genome and -transcriptome profiling of 496 consecutively recruited children with poor-prognosis cancer to identify genetic variants linked to cancer risk.Results:Integration of tumor and germline molecular profiling identified GPVs in 15.5% of patients, an incremental GPV yield of 7.9% above that detected by standard care. Although the cancer type was outside the recognized phenotypic spectrum for 43.7% of reported GPVs, 63.2% of these were clinically actionable. Integrated germline-tumor analysis increased the GPV detection rate by 8.5%, informed germline interpretation in 14.3% of patients with GPVs, and provided biological insight into tumor etiology, together highlighting the value of integrated analyses. Cascade testing in first-degree relatives confirmed that the GPV was de novo in 21% of tested families. Within inherited GPVs (73.9%), 47.8% had direct implications for risk management recommendations in the relevant parent.Conclusions:Our findings establish the clinical benefit and feasibility of integrated tumor–germline whole-genome screening to detect GPVs in children with poor-prognosis cancers and their first-degree relatives.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Purpose:The role of germline predisposition in pediatric cancer is increasingly recognized. However, the optimal approach to identifying cancer predisposing germline pathogenic variants (GPV) in children, and even the prevalence of GPVs among children with cancer, remain unclear. We examined GPV prevalence and diagnostic yield of different test approaches within a national pediatric precision oncology program.Experimental Design:We performed prospective rapid-turnaround whole-genome and -transcriptome profiling of 496 consecutively recruited children with poor-prognosis cancer to identify genetic variants linked to cancer risk.Results:Integration of tumor and germline molecular profiling identified GPVs in 15.5% of patients, an incremental GPV yield of 7.9% above that detected by standard care. Although the cancer type was outside the recognized phenotypic spectrum for 43.7% of reported GPVs, 63.2% of these were clinically actionable. Integrated germline-tumor analysis increased the GPV detection rate by 8.5%, informed germline interpretation in 14.3% of patients with GPVs, and provided biological insight into tumor etiology, together highlighting the value of integrated analyses. Cascade testing in first-degree relatives confirmed that the GPV was de novo in 21% of tested families. Within inherited GPVs (73.9%), 47.8% had direct implications for risk management recommendations in the relevant parent.Conclusions:Our findings establish the clinical benefit and feasibility of integrated tumor–germline whole-genome screening to detect GPVs in children with poor-prognosis cancers and their first-degree relatives.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Survey Instruments for Oncology and Genetics Clinicians
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Survey Instruments for Oncology and Genetics Clinicians
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Representativeness of Study Participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Characteristics of the 131 individuals within the sarcoma group
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Characteristics of the 131 individuals within the sarcoma group
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Genes examined for germline pathogenic variants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Genes examined for germline pathogenic variants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Patient and variant characteristics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Patient and variant characteristics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
List of cancer predisposition genes included in variant burden testing
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
List of cancer predisposition genes included in variant burden testing
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Penetrance category assigned to each cancer predisposition gene
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer
Penetrance category assigned to each cancer predisposition gene